The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience

Conclusion: Our data suggest that KRAS mutation is predictive of a superior response to immunotherapy. Furthermore, the lack of response of STK11 and KRAS co-mutated NSCLC patients to ICIs, is indeed negated by an additional TP53 mutation.

Source: Cancer Genomics and Proteomics - October 27, 2019 Category: Cancer & Oncology Authors: TORRALVO, J., FRIEDLAENDER, A., ACHARD, V., ADDEO, A. Tags: Article Source Type: research